Protective monoclonal antibody targeting mycobacterial HBHA blocks the interaction with the novel attachment co-receptor NRP1 to inhibit Mycobacterium bovis entry.

Authors

Mengjin Qu, Xiangmei Zhou, Xianfeng Zhang, Chenggang Jiang, Zhuo Zhang, Shouping Hu, Fei Xiao, Xin Quan, Xin Ge, Zhigao Bu, Jingfei Wang, Guangwen Wang, Xijun He

Published in

Journal of advanced research. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

The immune protection conferred by Bacillus Calmette-Guérin (BCG) is insufficient, underscoring the urgent need for novel strategies to control tuberculosis (TB). Although antibody-mediated responses targeting mycobacterial cell wall antigens have been observed during infection, the precise mechanism by which antibodies resist TB pathogens remains unclear.
This study aims to elucidate the molecular mechanism by which protective monoclonal antibodies (mAbs) against Mycobacterium bovis (M. bovis) cell wall antigens resist M. bovis infection.
In this study, we employed immunization with M. bovis cell wall antigens to screen for protective mAbs and identify their corresponding antigens. The underlying mechanisms were investigated using Western blotting, molecular docking, CRISPR/Cas9, flow cytometry, ELISA, surface plasmon resonance (SPR) and animal experiments.
MAb 2H3 targeted a conserved conformational epitope (₁₆₁KKAAPAKKAAPAKKAAPA₁₇₈) in HBHA's heparin-binding domain, inhibiting bacterial attachment to epithelial cells and phagocytosis by macrophages and reducing bacterial loads in mice. HBHA interacted specifically with NRP1-coupled HS chain, whose interaction can be disrupted by mAb 2H3. ATWLPPR peptide TFA, a selective NRP1 inhibitor, reduced attachment and virulence of M. bovis through decreasing the NRP1 expression on cell membrane.
By screening of a protective mAb (2H3) against cell wall antigens and elucidating its mechanism in blocking the interaction between adhesin (HBHA) and host cell co-receptor (NRP1), this work establishes a valuable framework for advancing anti-tuberculosis research and prophylactic development.

PMID:
42612949
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.